Trial Profile
Phase II study of adjuvant chemotherapy with gemcitabine and regional arterial infusion of nafamostat mesilate for the patients with resectable pancreatic cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Aug 2022
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Nafamostat (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 20 Aug 2022 Status changed from recruiting to completed.
- 15 Aug 2011 New trial record